著者
Koichiro Kinugawa Naoki Sato Takayuki Inomata Moriyoshi Yasuda Yoshiyuki Shibasaki Toshiyuki Shimakawa
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
vol.82, no.5, pp.1344-1350, 2018-04-25 (Released:2018-04-25)
参考文献数
16
被引用文献数
13 14

Background:It has been 7 years since tolvaptan was approved in Japan for the indication of heart failure in patients with volume overload; the drug can be used in patients with normonatremia. Hypernatremia was identified as a significant adverse event to be prevented.Methods and Results:We compiled and analyzed data from 3,349 patients over 5 years to identify patients at high risk of hypernatremia with tolvaptan treatment. The incidence of hypernatremia, defined as serum sodium ≥150 mEq/L, was 3.65%. Baseline serum sodium concentrations, serum potassium concentrations, blood urea nitrogen : creatinine ratio, initial tolvaptan dose, and age were identified as risk factors for hypernatremia. A hypernatremia risk score was developed using the odds ratios for these factors. The high-risk population was defined as patients with a risk score ≥17.80.Conclusions:To prevent the occurrence of hypernatremic events in patients taking tolvaptan, we recommend a very low starting dose (i.e., 3.75 mg/day) in patients identified as being at high risk of hypernatremia using our new scoring process.

言及状況

外部データベース (DOI)

Twitter (36 users, 37 posts, 322 favorites)

トルバプタン用量は少ないほど高Na血症のリスクが少なかった。 Novel Risk Score Efficiently Prevents Tolvaptan-Induced Hypernatremic Events in Patients With Heart Failure #InternMed 2018 https://t.co/Xvah4XLVGF
サムスカの高ナトリウム血症のリスクに関する日本の論文。 開始してどれくらいで高ナトリウムになるかの図が用量毎でわかりやすい。 リスクが高い場合でも、3.75mgで開始すれば高ナトリウムになる可能性は高くないことがわかります(添付文書の記載を守るのは大事です) https://t.co/HLvr48noWB https://t.co/6SSA3Y0hhN

収集済み URL リスト